



OPEN

# Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease

Maheshwar Lakkireddy<sup>1</sup>, Srikanth Goud Gadiga<sup>2</sup>, R. D. Malathi<sup>2</sup>, Madhu Latha Karra<sup>1✉</sup>, I. S. S. V. Prasad Murthy Raju<sup>2</sup>, Ragini<sup>2</sup>, Sangeetha Chinapaka<sup>2</sup>, K. S. S. Sai Baba<sup>1</sup> & Manohar Kandakatla<sup>1</sup>

COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19. Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0th day and 9th/11th day as per their respective BMI category. Subjects were randomised into VD and NVD groups. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from  $16 \pm 6$  ng/ml to  $89 \pm 32$  ng/ml after Pulse D therapy in VD group and highly significant ( $p < 0.01$ ) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant ( $p > 0.05$ ). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant ( $p < 0.01$ ). Therapeutic improvement in vitamin D to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.

COVID-19 pandemic caused by SARS-CoV-2 virus has created an unprecedented hardship in the recent times<sup>1,2</sup>. Serious consequences of COVID-19 were attributed to the immune dysregulation leading to the enhanced production of pro-inflammatory mediators (cytokine storm)<sup>3–7</sup>. In the absence of a specific vaccine or a treatment, strategies to minimize the effects of COVID-19 have become extremely important. Recent observational studies have reported that the patients with higher levels of serum vitamin D (vit.D) had less severe symptoms and vice versa and have postulated the usefulness of vit.D in prevention and treatment of COVID-19<sup>3,8–12</sup>. The beneficial effects of vit.D in COVID-19 were attributed to be mediated through its multiple actions on the immune system. Vit.D is known to enhance the production of various anti-microbial peptides by the immune cells and vit.D modulates the immune system according to the internal milieu. It reduces the dysregulated production of self-damaging pro-inflammatory cytokines and promotes the expression of anti-inflammatory cytokines by immune cells<sup>13–18</sup>. The dynamic role of vit.D can be of immense value in the context of immune dysfunction observed in COVID-19 patients with cytokine storm and acute respiratory distress syndrome<sup>2–6</sup>.

Though the protective immuno-modulatory effects of vit.D were explored in many autoimmune diseases and respiratory tract infections, there is a dearth of information from the randomised clinical trials in COVID-19.

Pulse D therapy is a targeted approach to increase the serum vit.D level by using high dose (60,000 IUs) oral supplementation of vit.D daily for a specific period of time determined by the individual's BMI, initial level of vit.D and the formulation<sup>19</sup>.

This study aims to objectively investigate the role of vit.D and the impact of Pulse D therapy in reducing the inflammatory biomarkers of COVID-19.

<sup>1</sup>Department of Orthopaedics/ Biochemistry/ Internal Medicine, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India. <sup>2</sup>Department of General Medicine/ Biochemistry, Gandhi Medical College, Secunderabad, Telangana, India. ✉email: madhu.harini123@gmail.com

## Material and methods

This is a randomised prospective open label parallel assignment interventional clinical trial carried out at Gandhi Medical College, Hospital Secunderabad in collaboration with Nizam's Institute of Medical Sciences, Hyderabad after receiving the approval of the Institutional ethics committee (IEC) of Gandhi Medical College (DCGI Regd. No: ECR/180/Inst/AP/2013/RR-19 dt.26-09-2019) vide Rc. No: IEC/GMC/2020/05/04 dt. 23-05-2020 with prior intimation, as per rules, to IEC Nizam's Institute of Medical Sciences, Hyderabad. COSORT 2010, WHO, ICMJE, ICMR and guidelines set out by Institutional ethics committees of Gandhi Medical College and Nizam's Institute of Medical Sciences were followed. This trial was registered in Clinical Trials Registry of India (CTRI) vide Clinical Trial Registration No: CTRI/2020/12/030083 dated: 29/12/2020, Reference No: REF/2020/12/039236. Written informed consent was taken from all the subjects and all the relevant rules and regulations were followed. Confirmed COVID-19 patients above the age of 18 years with hypovitaminosis D (vit.D level below 30 ng/ml) and mild to moderate illness ( $\text{SpO}_2 > 90\%$ ) as per the revised guidelines for COVID-19 issued by the Directorate General of Health Services, Government of India on 31-03-2020 were included. Patients with severe illness and patients who have taken high dose vit.D (60,000 IUs) in the last 3 months, patients with active malignancy, chronic renal disease and HIV, pregnant and breastfeeding mothers were excluded.

After admission, mild to moderately ill patients were allotted the serial numbers and were screened for serum vit.D level along with inflammatory markers of COVID-19. Haemogram with neutrophil/lymphocyte (N/L) ratio was performed on Mindray BC-6200 machine (Shenzhen Mindray Bio-Medical Electronics Co Ltd, Shenzhen, Guangdong sheng, China) using scatter fluorescence cube method. Vit.D, Serum Ferritin and Interleukin 6 (IL6) were estimated on Advia Centaur XPT machine (Siemens Healthineers, Erlangen, Germany) using direct chemiluminometric antibody competitive immunoassay method, direct chemiluminometric two-site sandwich immunoassay method and direct chemiluminometric one step immunoassay method respectively. Lactate dehydrogenase (LDH) and C reactive protein (CRP) were estimated on AU5800 Beckman Coulter machine (Beckman Coulter Inc., Brea CA, USA) using photometric kinetic UV-IFCC and photometric immunoturbidimetric methods respectively.

Patients with hypovitaminosis D were randomised into two groups vis a vis Experimental group/vit.D group (VD Group) and Active comparator/control group (NVD group) alternatively as per their pre allotment serial numbers. Subjects of VD group received adjunctive Pulse D therapy (60,000 IUs of vit.D in the form of aqueous nano solution (Deksel) per day for 8 days for subjects with body mass index (BMI) of 18–25 and 10 days for subjects with BMI > 25) along with the routine standard treatment for COVID-19. Subjects of NVD group received standard treatment for COVID-19 alone. After the completion of treatment with vit.D, repeat serum samples for vit.D and the inflammatory markers were collected on 9th or 11th day respectively for VD group. Similarly, samples were collected on 9th day for patients with BMI of 16–25 and 11th day for patients with BMI > 25 in NVD group.

Subjects in both the groups (VD and NVD) who have not received the drugs like Remdesivir, Favipiravir, Ivermectin or Dexamethasone were sub categorised into eVD and eNVD sub groups. Exclusive role of vit.D (without the influence of antiviral drugs or corticosteroids) in reducing the inflammatory markers of COVID-19 was studied in these subgroups.

Differences in the serum parameters between the two groups were analysed for statistical significance using MedCalc (Ver.19.5.1). Descriptive statistics of parametric variables were represented by Mean  $\pm$  SD and significance analysis by t test. Non parametric variables were represented by Median and IQR and comparative analysis by Mann–Whitney U test and Wilcoxon rank test.  $p$  value < 0.05 was considered statistically significant and  $p$  < 0.01 as highly significant.

Sample size calculation was done through openepi.com. Two sided confidence interval was taken as 95%, power as 80%, ratio of sample size as 1. The mean  $\pm$  SD difference of variables was taken as 50% in VD group and 10% in NVD group. Sample size thus derived was 13 for each group. To overcome the non responder's bias, sample size was adjusted by assuming an expected response proportion of 50%. Though the adjusted sample size was 26 in each group, 65 patients ( $n = 2.5 \times \text{sample size}$ ) were recruited for better outcome.

Prefix “pre” was used for an analyte before treatment and Prefix “Post” was used for an analyte after treatment. Prefix “Diff.in” was used to denote the difference (i.e. Pre/before treatment-Post/after treatment) in a given parameter.

## Results

One hundred and thirty confirmed COVID-19 subjects were included and 87 subjects could complete the study. Details are enumerated in the flow diagram (Fig. 1).

The mean age of patients who have completed the study ( $n = 87$ ) was  $45 \pm 13$  years, range 20–83 years. The mean age of patients in VD group ( $n = 44$ ) was  $47 \pm 12$  years, range 20–70 years and in NVD group ( $n = 43$ ) was  $44 \pm 14$  years, range 20–83 years. There was no significant difference in age between the two groups ( $p = 0.23$ ).

There was no significant difference in median BMI between the patients in VD (25) and NVD (24) groups ( $Z = -0.8$ ,  $p = 0.4$ ). There was no significant difference in the median duration of symptoms between the patients in VD (5 days) and NVD (5 days) groups ( $Z = 0.9$ ,  $p = 0.4$ ).

There was no significant difference ( $p > 0.05$ ) in vital parameters between NVD and VD groups (median systolic blood pressure:  $p = 0.9$ , mean diastolic blood pressure:  $p = 0.4$ , median heart rate:  $p = 0.3$ , median  $\text{SpO}_2$ :  $p = 0.8$ ) at the time of enrolment.

34 out of the 87 subjects who have completed the study had either diabetes or hypertension as co-morbidity (39%). Owing to randomisation, 21 and 13 subjects with co-morbidities were allotted to VD and NVD group respectively. There was no significant difference ( $p > 0.05$ ) in levels of all the measured inflammatory markers in the subjects of both groups with and without co-morbidities before and after treatment.




**Figure 1.** CONSORT flow diagram.

Out of the 87 subjects who have completed the study, 75% (n = 65) were men and 25% (n = 22) were women. Owing to randomisation n = 37, 28 men and n = 7, 15 women got allotted to VD and NVD groups respectively. The difference in the inflammatory markers before treatment between the genders in VD and NVD groups was not significant ( $p > 0.05$ ) except for IL6 ( $p = 0.02$ ) in VD group and Ferritin ( $p = 0.002$ ) in NVD group with men having higher levels. The difference in the inflammatory markers after treatment between the genders in VD and NVD groups was not significant ( $p > 0.05$ ) except for higher CRP ( $p = 0.02$ ) in women and higher Ferritin ( $p = 0.002$ ) in men in NVD group.

In spite of matching various independent parameters, significant difference ( $p < 0.05$ ) in all the inflammatory markers between VD and NVD groups was noted before treatment with all the markers being high in VD group.

Analysis of inflammatory markers and vit.D in the VD group before versus after treatment has shown highly significant reduction ( $p < 0.01$ ) in all the measured inflammatory markers and a significant increase ( $p < 0.01$ ) in vit.D (Table 1).

Unlike the VD group, analysis of inflammatory markers in the NVD group before and after treatment has not shown significant reduction ( $p > 0.05$ ) except CRP. On the contrary levels of IL6 and Ferritin have increased though they were not significant statistically (Table 2).

The difference in the reduction of inflammatory markers between the two groups (NVD vs VD) was highly significant ( $p < 0.01$ ) with the reduction in VD group being markedly higher than the NVD group (Table 3).

Fifteen cases each in VD and NVD group have not received any drugs like Remdesivir, Favipiravir, Ivermectin or Dexamethasone. Analysis of inflammatory markers in the eVD sub group (before and after treatment) has shown highly significant reduction ( $p < 0.01$ ) in all the measured inflammatory markers after Pulse D therapy. Significant increase in vit.D level was noted ( $p < 0.01$ ) (Table 4).

| Variable         | Pre (n = 44)                  |                       | Post (n = 44)                 |                       | Pre vs Post      |          |
|------------------|-------------------------------|-----------------------|-------------------------------|-----------------------|------------------|----------|
|                  | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | t or z statistic | p value  |
| Vit.D (ng/ml)    | 16 $\pm$ 6 <sup>#</sup>       | 14–17 <sup>*</sup>    | 89 $\pm$ 32 <sup>#</sup>      | 79–99 <sup>*</sup>    | 16               | < 0.0001 |
| CRP (mg/l)       | 81 $\pm$ 66 <sup>#</sup>      | 61–101 <sup>*</sup>   | 16 $\pm$ 42 <sup>#</sup>      | 4–29 <sup>*</sup>     | – 6              | < 0.0001 |
| LDH (U/l)        | 369 $\pm$ 159 <sup>#</sup>    | 321–418 <sup>*</sup>  | 274 $\pm$ 115 <sup>#</sup>    | 240–309 <sup>*</sup>  | – 5              | < 0.0001 |
| IL6 (pg/ml)      | 15 (5–57)                     | 9–29                  | 3 (0.9–6)                     | 2–5                   | 4                | < 0.0001 |
| Ferritin (ng/ml) | 431 (190–836)                 | 262–708               | 334 (154–508)                 | 203–433               | 4                | 0.0004   |
| N/L ratio        | 5 (3–11)                      | 4–8                   | 3 (2–5)                       | 3–5                   | 4                | 0.0003   |

**Table 1.** Values of various parameters studied in the VD group before and after treatment. *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

| Variable         | Pre (n = 43)                  |                       | Post (n = 43)                 |                       | Pre vs Post      |         |
|------------------|-------------------------------|-----------------------|-------------------------------|-----------------------|------------------|---------|
|                  | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | t or z statistic | p value |
| Vit.D (ng/ml)    | 17 $\pm$ 6 <sup>#</sup>       | 15–19 <sup>*</sup>    | 16 $\pm$ 7 <sup>#</sup>       | 14–18 <sup>*</sup>    | – 0.1            | 0.5     |
| CRP (mg/l)       | 11 (3–43)                     | 5–30                  | 5 (1–9)                       | 2–7                   | 3                | 0.008   |
| LDH (U/l)        | 244 (172–298)                 | 189–263               | 207 (175–251)                 | 190–224               | 1                | 0.2     |
| IL6 (pg/ml)      | 3 (1–9)                       | 1–6                   | 4 (1–11)                      | 1–7                   | – 0.1            | 0.9     |
| Ferritin (ng/ml) | 169 (63–526)                  | 87–329                | 196 (54–456)                  | 68–331                | 2                | 0.07    |
| N/L ratio        | 3 (2–5)                       | 2–4                   | 2 (2–4)                       | 2–3                   | 0.3              | 0.8     |

**Table 2.** Values of various parameters studied in the NVD group before and after treatment. *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

| Variable         | NVD (n = 43)     |                  | VD (n = 44)       |                  | NVD vs VD   |          |
|------------------|------------------|------------------|-------------------|------------------|-------------|----------|
|                  | Median (IQR)     | 95% CI of median | Median (IQR)      | 95% CI of median | z statistic | p value  |
| Vit.D (ng/ml)    | – 0.1 (– 3 to 5) | – 1 to 3         | – 64 (– 92 to 52) | – 81 to 58       | 8           | < 0.0001 |
| CRP (mg/l)       | 5 (– 3 to 39)    | – 0.003 to 21    | 51 (10 to 113)    | 30 to 85         | – 4         | 0.0001   |
| LDH (U/l)        | 15 (– 22 to 60)  | – 13 to 40       | 72 (13 to 168)    | 48 to 133        | 3           | 0.002    |
| IL6 (pg/ml)      | 0.5 (– 7 to 4)   | – 4 to 1         | 13 (2 to 46)      | 8 to 25          | – 4         | 0.0002   |
| Ferritin (ng/ml) | 11 (11 to 55)    | – 6 to 38        | 84 (8 to 268)     | 55 to 171        | 3           | 0.008    |
| N/L ratio        | 0.05 (– 1 to 2)  | – 0.7 to 1       | 0.9 (0 to 5)      | 0.3 to 2         | – 3         | 0.009    |

**Table 3.** The values of difference in the inflammatory markers and vitamin D between the two groups (NVD vs VD). *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

| Variable         | Pre (n = 15)                  |                       | Post (n = 15)                 |                       | Pre vs Post      |          |
|------------------|-------------------------------|-----------------------|-------------------------------|-----------------------|------------------|----------|
|                  | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | t or z statistic | p value  |
| Vit.D (ng/ml)    | 15 $\pm$ 5 <sup>#</sup>       | 12–18 <sup>*</sup>    | 81 $\pm$ 32 <sup>#</sup>      | 64–99 <sup>*</sup>    | 8                | < 0.0001 |
| LDH (U/l)        | 385 $\pm$ 206 <sup>#</sup>    | 271–499 <sup>*</sup>  | 254 $\pm$ 84 <sup>#</sup>     | 208–300 <sup>*</sup>  | – 3              | 0.007    |
| IL6 (pg/ml)      | 33 $\pm$ 35 <sup>#</sup>      | 14–52 <sup>*</sup>    | 3 $\pm$ 4 <sup>#</sup>        | 1–5 <sup>*</sup>      | – 3              | 0.004    |
| CRP (mg/l)       | 57 (22–96)                    | 22–96                 | 8 (3–16)                      | 3–16                  | 3                | 0.0003   |
| Ferritin (ng/ml) | 207 (126–565)                 | 126–565               | 186 (94–423)                  | 94–423                | 13               | 0.005    |
| N/L ratio        | 6 (3–13)                      | 3–12                  | 3 (2–4)                       | 2–4                   | 11               | 0.003    |

**Table 4.** Values of various parameters analysed in the eVD sub group before and after treatment. *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

| Variable         | Pre (n = 15)                  |                       | Post (n = 15)                 |                       | Pre vs Post      |         |
|------------------|-------------------------------|-----------------------|-------------------------------|-----------------------|------------------|---------|
|                  | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | t or z statistic | p value |
| Vit.D (ng/ml)    | 16 $\pm$ 6 <sup>#</sup>       | 13–19 <sup>*</sup>    | 17 $\pm$ 8 <sup>#</sup>       | 12–21 <sup>*</sup>    | 0.2              | 0.8     |
| LDH (U/l)        | 257 $\pm$ 106 <sup>#</sup>    | 198–316 <sup>*</sup>  | 235 $\pm$ 88 <sup>#</sup>     | 186–284 <sup>*</sup>  | – 0.9            | 0.4     |
| IL6 (pg/ml)      | 4 (2–9)                       | 2–9                   | 1 (0–9)                       | 0–9                   | 49               | 0.6     |
| CRP (mg/l)       | 8 (2–19)                      | 2–19                  | 5 (2–8)                       | 2–8                   | 42               | 0.3     |
| Ferritin (ng/ml) | 147 (65–230)                  | 65–229                | 189 (51–237)                  | 51–237                | 51               | 0.6     |
| N/L ratio        | 2 (1–3)                       | 1–3                   | 2 (2–5)                       | 2–5                   | 24               | 0.04    |

**Table 5.** Values of various parameters analysed in the eNVD sub group before and after treatment. *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

| Difference in variable (pre–post) | eNVD (n = 15)                 |                         | eVD (n = 15)                  |                       | eNVD vs eVD      |         |
|-----------------------------------|-------------------------------|-------------------------|-------------------------------|-----------------------|------------------|---------|
|                                   | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median   | Mean $\pm$ SD or median (IQR) | 95% CI of mean/median | t or z statistic | p value |
| IL6 (pg/ml)                       | 3 $\pm$ 28 <sup>#</sup>       | – 13 to 18 <sup>*</sup> | 30 $\pm$ 34 <sup>#</sup>      | 11 to 49 <sup>*</sup> | 2                | 0.02    |
| Vit.D (ng/ml)                     | – 1 (– 6 to 4)                | – 6 to 4                | – 63 (– 75 to 48)             | – 75 to 48            | 5                | <0.0001 |
| LDH (U/l)                         | – 0.6 (– 22 to 64)            | – 22 to 63              | 73 (42 to 204)                | 42 to 203             | 2                | 0.02    |
| CRP (mg/l)                        | 0.7 (– 2.35 to 12.98)         | 2 to 13                 | 39 (17 to 84)                 | 17 to 84              | 3                | 0.001   |
| Ferritin (ng/ml)                  | 1 (– 12 to 55)                | – 12 to 55              | 76 (6 to 156)                 | 6 to 158              | 2                | 0.07    |
| N/L ratio                         | – 0.5 (– 1 to 0.01)           | – 1 to 0.01             | 1.0 (0.07 to 5)               | 0.08 to 5             | 3                | 0.0006  |

**Table 6.** Values of difference in the inflammatory markers and vitamin D between the sub groups (eNVD vs eVD). *Vit.D* Vitamin D, *CRP* C-reactive protein, *LDH* Lactate dehydrogenase, *IL-6* Interleukin-6, *N/L ratio* Neutrophil/Lymphocyte ratio, *IQR* Interquartile range, <sup>#</sup>mean  $\pm$  SD, <sup>\*</sup>95% CI of mean.

Analysis of inflammatory markers in the eNVD sub group (before and after treatment) has not shown any significant reduction ( $p > 0.05$ ). The levels of Ferritin ( $p > 0.05$ ) and N/L ratio ( $p < 0.05$ ) on the contrary have increased in the post samples when compared to the pre samples (Table 5).

The difference in the reduction of inflammatory markers between the two sub groups (eNVD vs eVD) was significant ( $p < 0.05$ ) with the reduction in eVD sub group being markedly higher than the eNVD sub group except for Ferritin. Though the reduction of median Ferritin levels after Pulse D therapy was quite high in the VD group, it was not statistically significant (Table 6).

Difference in the mean hospital stay between VD vs NVD groups ( $13 \pm 5$  days vs  $14 \pm 5$  days) was not significant ( $p = 0.9$ ).

Intensive care support was required for 9 subjects (VD group:  $n = 4$ , NVD group:  $n = 5$ ) and 7 of them died (VD group:  $n = 2$ , NVD group:  $n = 5$ ). 6 out of these 7 subjects (VD group:  $n = 2$ , NVD group:  $n = 4$ ) died after  $5 \pm 1$  day of enrolment without completing the study. One subject in NVD group died after 21 days of enrolment. All of them had very high levels of inflammatory markers at admission when compared to the survivors. The difference was highly significant ( $p < 0.01$ ) for IL6, CRP, Ferritin and significant ( $p = 0.02$ ) for N/L ratio and LDH. 2 of the 7 non survivor subjects (28.5%) had either diabetes or hypertension as co-morbidity.

No adverse reactions attributable to vit.D toxicity were noted in any of the patients studied. Serum calcium level in VD group after treatment was within normal limits ( $9 \pm 0.5$  mg/dl).

## Discussion

COVID-19 caused by SARS-CoV-2 (novel corona virus) has not only incited intense adaptive immune response in the individuals who were affected by it but also has incited immense human response at various fronts to fight it all over the world<sup>4,5</sup>. As the immune dysregulation caused by COVID-19 lead to respiratory failure and multi organ dysfunction syndrome, many attempts were made to repurpose the available drugs to address the challenges posed by the novel corona virus<sup>4,6,7,20,21</sup>. Mortality and morbidity were recorded to be high in patients with significantly elevated inflammatory markers (surrogate markers of COVID-19 severity) such as N/L ratio, CRP, LDH, IL6, Ferritin, D dimer etc<sup>3,6,7,11,22</sup>. Similarly, mortality and morbidity were also recorded to be high in patients with vit.D deficiency<sup>9,11,12</sup>. Low vit.D level was proposed to be an independent risk factor for acquiring COVID-19 infection, hospitalization and COVID-19 related mortality<sup>9,10</sup>. Based on the earlier evidence that vit.D could decrease the incidence of flu and other respiratory infections and the observational studies in COVID-19, few hypothesis and recommendations have been published in support of supplementing vit.D to avert the serious consequences of COVID-19<sup>2,3,9–12,23,24</sup>. Kaufman et al. reported that SARS-CoV-2 positivity is strongly and inversely associated with serum vitamin D level and proposed that vitamin D supplementation could reduce the risk of SARS-CoV-2 infection and COVID-19 disease<sup>25</sup>.

Vit.D has innumerable effects on human physiology. In addition to its endocrinal and calcitropic musculoskeletal effects, it is a potential immunomodulator. Depending upon the prevailing internal milieu and the level of 25 hydroxy vitamin D in the blood, intracrine activation of 1 $\alpha$  hydroxylase occurs in the immune cells to produce calcitriol locally and have its autocrine effects like promotion of innate immune response to infections and modulation of adaptive immune response. Vit.D acts as a smart switch to decrease the Th1 response and pro inflammatory cytokines while enhancing the production of anti-inflammatory cytokines in cases of immune dysregulation<sup>13–16,23</sup>. It is pertinent to note that SARS-CoV-2 virus activates Th1 response and suppresses Th2 response<sup>4</sup>. It was postulated that the levels of vit.D above 40–60 ng/ml could be protective to tide over the COVID-19 crisis<sup>8,11,26</sup>. Annweiler et al. reported that the hospitalised frail elderly patients who had regularly taken bolus vitamin D supplementation before hospitalisation with COVID-19 had significantly better survival rates than others<sup>27</sup>. In a retrospective analysis, Ling et al. reported a reduced risk of mortality in COVID 19 patients treated with high dose cholecalciferol booster therapy<sup>28</sup>. Owing to the paucity of evidence from prospective randomised clinical trials, high dose vit.D was not included in the existing treatment protocols of COVID-19. Few randomised control trials using bolus doses of vitamin D in COVID-19 are yet to be completed and reported<sup>29</sup>. McNally et al. reported that rapid normalization of vitamin D levels can be achieved with loading therapy, duly considering the disease status, baseline vit.D level and weight but loading doses > 3,00,000 IU were advised to be avoided until trials are conducted to evaluate the risk and benefit<sup>30</sup>. Intermittent bolus dose vit.D therapies with 3 monthly gaps have failed to achieve the target levels<sup>31</sup>.

As the concentration dependent effects of vit.D on the immune system and the means to achieve such concentrations safely in the shortest possible time in a given individual is known<sup>19,30,32</sup>, we have carried out this study to determine the impact of Pulse D therapy on the inflammatory markers of COVID-19.

The two randomised groups in our study were matched with respect to age, BMI, duration of symptoms, co-morbidities and vital parameters. In spite of the matching of various parameters, significant difference in markers before treatment between the groups was intriguing. This difference can be attributed to chance alone. Male predominance (75% vs 25%) was noted akin to earlier reports<sup>3</sup>. Analysis of inflammatory markers before and after treatment in VD group has shown highly significant reduction ( $p < 0.01$ ) in all the inflammatory markers after adjunctive pulse D therapy. On the contrary insignificant reduction ( $p > 0.05$ ) of inflammatory markers was noted in the NVD group. The difference in reduction of inflammatory markers between the groups (NVD vs VD) was highly significant ( $p < 0.01$ ) with the reduction of markers being markedly high in VD group when compared to the NVD group. Hence, adjunctive Pulse D therapy targeted at a mean vit D level of 80–100 ng/ml has effectively reduced the inflammatory markers associated with cytokine storm and COVID-19 severity.

Rastogi et al. reported that high dose vit.D supplementation orally for seven consecutive days has increased the vit.D level in a group of 16 patients from 8.6 to 42.4 ng/ml with significant reduction in fibrinogen levels and insignificant reduction in CRP. Early viral clearance in the form of negative RT-PCR after vit.D supplementation was also reported<sup>1</sup>.

Entrenas Castillo et al. reported that oral administration of high dose calcifediol has significantly reduced the severity of COVID-19, need for ICU treatment and mortality. Though elevated levels of inflammatory markers at enrolment were reported, initial level of vitamin D or the follow up levels of vitamin D or inflammatory markers was not studied<sup>33</sup>.

It may be noted that the statistically significant reduction of all the inflammatory markers in this study may be attributed to the level of vit.D achieved ( $89 \pm 32$  ng/ml) and aqueol nano formulation (Deksel) has facilitated the target levels to be achieved, akin to an earlier report<sup>19</sup>. Significant reduction in CRP was noted in our study when compared to the report of Rastogi et al.<sup>1</sup>. This may be attributed to the difference in the level of vit.D after treatment. As per our knowledge, these findings are the first of its kind to be reported.

We have analysed the inflammatory markers in a separate subset of cases (eVD and eNVD sub groups) derived from both the study groups who have not received any drugs like Remdesivir, Favipiravir or Ivermectin or Dexamethasone. Highly significant reduction ( $p < 0.01$ ) in all the measured inflammatory markers with significant increase in vit.D was noted in the eVD sub group unlike the eNVD sub group ( $p > 0.05$ ). The difference in reduction of inflammatory markers between the sub groups (eNVD vs eVD) was highly significant ( $p < 0.01$ ) with the reduction of markers being markedly high in eVD subgroup when compared to the eNVD sub group. Hence, improvement in serum vit.D level to 80 ng/ml has shown to effectively reduce the levels of surrogate markers of COVID-19 severity/cytokine storm independently. These findings are exclusive to our study as on date and could not be compared with others.

DiNicolantonio et al. reported that both magnesium and vitamin D are important to the immune system independently. Together, they may be beneficial in COVID-19 infection as magnesium is necessary to activate vitamin D. Results from our study can be compared with the results of future studies with and without magnesium in high dose vitamin D regimens to formulate effective dosing schedules<sup>34</sup>.

Hospital stay was subjective and multifactorial in both the groups. It could not be attributed to the physical impact of the disease alone. Murai et al. reported that, a single high dose vitamin D3 (2,00,000 IU) supplementation has not reduced the length of hospital stay, mortality or ICU admission significantly when compared to placebo. Their findings did not support the use of single bolus dose of vitamin D3 for treatment of moderate to severe COVID-19<sup>35</sup>.

At enrolment, significantly higher levels of all the inflammatory markers were noted in the non survivors compared to survivors. Similar relationship of mortality to the elevated levels of inflammatory markers was reported by Jain et al. in their observational study<sup>3</sup>.

No adverse reactions to vit.D were reported in our study. Serum calcium levels were within the normal limits after treatment ( $9 \pm 0.5$  mg/dl) in VD group. Similar finding on the safety of short-term high dose vit.D supplementation were reported by Rastogi et al. and in long term by McCullough et al.<sup>1,36</sup>. De Carvalho et al.

reported that mega doses (6,00,000 IU) of vitamin D administered through intramuscular route even in cases of nephrolithiasis are safe<sup>37</sup>.

# Conclusions

Immune dysregulation in COVID-19 is marked by increased inflammatory biomarkers such as N/L ratio, CRP, LDH, IL6 and Ferritin. Vitamin D is a potential immunomodulator and its adjunctive role in the treatment of COVID-19 is established by this study. Improvement of serum vit.D level to 80–100 ng/ml has significantly reduced the inflammatory markers without any side effects. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19.

# Limitations of the study

This is a single centre study. It can be considered as a pilot for larger multicentric RCTs in future.

Received: 21 January 2021; Accepted: 7 May 2021

Published online: 20 May 2021

# References

- Rastogi, A. *et al.* Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study). *Postgrad. Med. J.* <https://doi.org/10.1136/postgradmedj-2020-139065> (2020).
- Aygun, H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. *Naunyn. Schmiedebergs Arch. Pharmacol.* **393**(7), 1157–1160. <https://doi.org/10.1007/s00210-020-01911-4> (2020).
- Jain, A. *et al.* Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. *Sci. Rep.* **10**(1), 20191. <https://doi.org/10.1038/s41598-020-77093-z> (2020).
- Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) (2020).
- Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J. Infect.* **80**(6), 607–613. <https://doi.org/10.1016/j.jinf.2020.03.037> (2020).
- Chen, L. *et al.* Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi* **43**, E005. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005> (2020).
- Chen, G. *et al.* Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Invest.* **130**(5), 2620–2629. <https://doi.org/10.1172/JCI137244> (2020).
- Grant, W. B. *et al.* Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* **12**(4), 988. <https://doi.org/10.3390/nu12040988> (2020).
- De Smet, D., De Smet, K., Herroelen, P., Gryspeerdt, S. & Martens, G. A. Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. *Am. J. Clin. Pathol.* <https://doi.org/10.1093/ajcp/aqaa252> (2020).
- Merzon, E. *et al.* Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: An Israeli population-based study. *FEBS J.* **287**(17), 3693–3702. <https://doi.org/10.1111/febs.15495> (2020).
- Maghbooli, Z. *et al.* Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. *PLoS One* **15**(9), e0239799. <https://doi.org/10.1371/journal.pone.0239799> (2020).
- Carpagnano, G. E. *et al.* Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J. Endocrinol. Invest.* **9**, 1–7. <https://doi.org/10.1007/s40618-020-01370-x> (2020).
- Chambers, E. S. & Hawrylowicz, C. M. The impact of vitamin D on regulatory T cells. *Curr. Allergy Asthma Rep.* **11**(1), 29–36. <https://doi.org/10.1007/s11882-010-0161-8> (2011).
- Adams, J. S. & Hewison, M. Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. *Nat. Clin. Pract. Endocrinol. Metab.* **4**(2), 80–90. <https://doi.org/10.1038/ncpendmet0716> (2008).
- Lemire, J. M. *et al.* 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. *J. Immunol.* **134**(5), 3032–3035 (1985).
- Gombart, A. F., Pierre, A. & Maggini, S. A Review of micronutrients and the immune system-working in harmony to reduce the risk of infection. *Nutrients* **12**(1), 236. <https://doi.org/10.3390/nu12010236> (2020).
- Meltzer, D. O. *et al.* Association of VITAMIN D status and other clinical characteristics with COVID-19 test results. *JAMA Netw. Open.* **3**(9), e2019722. <https://doi.org/10.1001/jamanetworkopen.2020.19722> (2020).
- Baeke, F., Takiishi, T., Korf, H., Gysemans, C. & Mathieu, C. Vitamin D: Modulator of the immune system. *Curr. Opin. Pharmacol.* **10**(4), 482–496. <https://doi.org/10.1016/j.coph.2010.04.001> (2010).
- Lakkireddy, M. *et al.* Efficiency of vitamin D supplementation in patients with mechanical low back ache. *J. Clin. Orthop. Trauma* **10**(6), 1101–1110. <https://doi.org/10.1016/j.jcot.2019.06.018> (2019).
- Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. *JAMA* **323**(18), 1824–1836. <https://doi.org/10.1001/jama.2020.6019> (2020).
- WHO Solidarity Trial Consortium *et al.* Repurposed antiviral drugs for covid-19-interim WHO Solidarity Trial Results. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2023184> (2020).
- Velavan, T. P. & Meyer, C. G. Mild versus severe COVID-19: Laboratory markers. *Int. J. Infect. Dis.* **95**, 304–307 (2020).
- Liu, G., Hong, T. & Yang, J. A single large dose of vitamin D could be used as a means of coronavirus disease 2019 prevention and treatment. *Drug Des. Dev. Ther.* **21**(14), 3429–3434. <https://doi.org/10.2147/DDDT.S271754> (2020).
- Giannini, S. *et al.* Effectiveness of in-hospital cholecalciferol use on clinical outcomes in comorbid COVID-19 patients: A hypothesis-generating study. *Nutrients* **13**(1), 219. <https://doi.org/10.3390/nu13010219> (2021).
- Kaufman, H. W., Niles, J. K., Kroll, M. H., Bi, C. & Holick, M. F. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS One* **15**(9), e0239252. <https://doi.org/10.1371/journal.pone.0239252> (2020).
- Ebadi, M. & Montano-Loza, A. J. Perspective: Improving vitamin D status in the management of COVID-19. *Eur. J. Clin. Nutr.* **74**(6), 856–859. <https://doi.org/10.1038/s41430-020-0661-0> (2020).
- Annweiler, G. *et al.* Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: The GERIA-COVID quasi-experimental study. *Nutrients* **12**(11), 3377. <https://doi.org/10.3390/nu12113377> (2020).
- Ling, S. F. *et al.* High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: A cross-sectional multi-centre observational study. *Nutrients* **12**(12), 3799. <https://doi.org/10.3390/nu12123799> (2020).
- Mariani, J. *et al.* High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL). *Trials* **22**(1), 111. <https://doi.org/10.1186/s13063-021-05073-3> (2021).
- McNally, J. D. *et al.* Rapid normalization of vitamin D levels: A meta-analysis. *Pediatrics* **135**(1), e152–e166. <https://doi.org/10.1542/peds.2014-1703> (2015).

31. Välimäki, V. V., Löyttyneemi, E., Pekkarinen, T. & Välimäki, M. J. How well are the optimal serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? A placebo-controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3 months in elderly women. *Clin. Endocrinol. (Oxf.)* **84**(6), 837–844. <https://doi.org/10.1111/cen.13014> (2016).
32. Wu, Z. *et al.* What factors modify the effect of monthly bolus dose vitamin D supplementation on 25-hydroxyvitamin D concentrations? *J. Steroid. Biochem. Mol. Biol.* **201**, 105687. <https://doi.org/10.1016/j.jsbmb.2020.105687> (2020).
33. Entrenas Castillo, M. *et al.* Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. *J. Steroid. Biochem. Mol. Biol.* **203**, 105751. <https://doi.org/10.1016/j.jsbmb.2020.105751> (2020).
34. DiNicolantonio, J. J. & O'Keefe, J. H. Magnesium and vitamin D deficiency as a potential cause of immune dysfunction, cytokine storm and disseminated intravascular coagulation in COVID-19 patients. *Mol. Med.* **118**(1), 68–73 (2021).
35. Murai, I. H. *et al.* Effect of a single high dose of Vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. *JAMA* **325**(11), 1053–1060. <https://doi.org/10.1001/jama.2020.26848> (2021).
36. McCullough, P. J., Lehrer, D. S. & Amend, J. Daily oral dosing of vitamin D3 using 5000 to 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience. *J. Steroid Biochem. Mol. Biol.* **189**, 228–239. <https://doi.org/10.1016/j.jsbmb.2018.12.010> (2019).
37. de Carvalho, J. F. & Churilov, L. P. Safety of megadose of vitamin D in patients with nephrolithiasis. *Nutrition* **12**(87–88), 111201. <https://doi.org/10.1016/j.nut.2021.111201> (2021).

## Acknowledgements

We express our gratitude to Dr. Raja Rao, Medical Superintendent, Dr. MD Suleman, Vice Principal, Dr. Vinay Shekar, HOD, Dept. of General Medicine, Dr. S U M Raju, Associate Professor of Pharmacology, Gandhi Medical College and Hospital for their kind support. We thank Mr. Mallesh Kothapally and Mr. Ravi Paili for their extensive support in carrying out this project.

## Author contributions

Study design: M.L., M.L.K., I.S.S.V.R. Data collection: S.G., R.D.M., I.S.S.V.R., R., S.C., M.L., M.L.K. Statistical analysis: M.L., M.L.K., K.S.S.S.B. Data interpretation: M.L., M.L.K., K.S.S.S.B., M.K. Manuscript preparation: M.L., M.L.K. Literature search: M.L., M.L.K., I.S.S.V.R., M.K. Funds collection: I.S.S.V.R., M.K., S.G., M.L.

## Funding

Sponsored by Pulse Pharmaceuticals. Funding source has no involvement in study design, collection, analysis, interpretation of data, writing the report or decision to submit the article for publication.

## Competing interests

The authors declare no competing interests.

## Additional information

**Correspondence** and requests for materials should be addressed to M.L.K.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021, corrected publication 2021